Abstract:Recent years have seen increased discussion surrounding the benefits of damage control resuscitation, prehospital transfusion (PHT) of blood products, and the use of whole blood over component therapy. Concurrent shortages of blood products with the desire to provide PHT during air medical transport have prompted reconsideration of the traditional approach of administering RhD-negative red cell-containing blood products first-line to females of childbearing potential (FCPs). Given that only 7% of the US population has blood type O negative and 38% has O positive, some programs may be limited to offering RhD-positive blood products to FCPs. Adopting the practice of giving RhD-positive blood products first-line to FCPs extends the benefits of PHT to such patients, but this practice does incur the risk of future hemolytic disease of the fetus and newborn (HDFN). Although the risk of future fetal mortality after an RhD-incompatible transfusion is estimated to be low in the setting of acute hemorrhage, the number of FCPs who are affected by this disease will increase as more air medical transport programs adopt this practice. The process of monitoring and managing HDFN can also be time intensive and costly regardless of the rates of fetal mortality. Air medical transport programs planning on performing PHT of RhD-positive red cell-containing products to FCPs should have a basic understanding of the pathophysiology, prevention, and management of hemolytic disease of the newborn before introducing this practice. Programs should additionally ensure there is a reliable process to notify receiving centers of potentially RhD-incompatible PHT because alloimmunization prophylaxis is time sensitive. Facilities receiving patients who have had PHT must be prepared to identify, counsel, and offer alloimmunization prophylaxis to these patients. This review aims to provide air medical transport professionals with an understanding of the pathophysiology and management of HDFN and provide a template for the early management of FCPs who have received an RhD-positive red cell-containing PHT. This review also covers the initial workup and long-term anticipatory guidance that receiving trauma centers must provide to FCPs who have received RhD-positive red cell-containing PHT.

Not as "D"eadly as once thought - the risk of D-alloimmunization and hemolytic disease of the fetus and newborn following RhD-positive transfusion in trauma

Ethical considerations in the use of RhD‐positive blood products in trauma

Management Considerations for Air Medical Transport Programs Transfusing RhD-Positive Red Blood Cell-Containing Products to Females of Childbearing Potential

Another piece of the hemolytic disease of the fetus and newborn puzzle after RhD-positive transfusion in trauma resuscitation: the proportion of pregnant women who produce high titer anti-D

Receipt of RhD‐positive whole blood for life‐threatening bleeding in female children: A survey in alloimmunized mothers regarding minimum acceptable survival benefit relative to risk of maternal alloimmunization to anti‐D

Survey of policies at US hospitals on the selection of RhD type of low‐titer O whole blood for use in trauma resuscitation

Timing of RhD-positive red blood cell administration is associated with D-alloimmunization in injured patients

Resuscitative practices and the use of low-titer group O whole blood in pediatric trauma

Neonatal and Obstetrical Outcomes of Pregnancies Complicated by Alloimmunization

Maternal and child life years gained by transfusing low titer group O whole blood in trauma: A computer simulation

Characterization of blood bank and transfusion medicine practices for pregnant individuals with fetuses at risk of hemolytic disease in the United States

Maternal red blood cell alloimmunization prevalence in the United States

Hemolytic disease of the fetus and newborn-a perspective of immunohematology

Non-RhD alloimmunization in pregnancy: an updated review

Low titer group O whole blood and risk of RhD alloimmunization: Rationale for use in Finland

RhD-positive red blood cell allocation practice to RhD-negative patients before and during the COVID-19 pandemic

Standard Compared With Extended Red Blood Cell Antigen Matching for Prevention of Subsequent Hemolytic Disease of the Fetus and Newborn: A Systematic Review

Why do RhD negative pregnant women still become anti-D immunized despite prophylaxis with anti-D immunoglobulin?

RhD‐negative red blood cells can be saved during liver transplantation in RhD‐negative patients due to low risk of alloimmunization against RhD

How I manage pregnant patients who are alloimmunized to RBC antigens

Rh immune globulin immunoprophylaxis after RhD‐positive red cell exposure in RhD‐negative patients via transfusion: A survey of practices